Arcutis Biotherapeutics, Inc.
ARQ-234
atopic dermatitis
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for ARQ-234 in atopic dermatitis are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Initiated Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor, in healthy volunteers and adults w”